GSK is expecting its cancer drug clinical pipeline to nearly double in 2027
Oncology chief Hesham Abdullah said GSK has about 15 cancer assets in trials and could run 19 to 20 late-stage studies next year
We haven't written up this one. Quartz has the full story — the link below goes straight to it.